絞り込み

16548

広告

中国 仏技術採用の新型原発 世界初の営業運転

原子力発電所の建設を積極的に推し進めている中国で、フランスの技術を採用した新型の原発が世界で初めて営業運転を開始し、東京電力福島第一原子力発電所の事故を受けて、...

  1. スマブラ「灯火の星」セリフ・低予算版&カ...
  2. 企業活動の及ぼす環境影響を貨幣価値に換算...
  3. [企業] Axovant社 ガングリオシ...
  4. 月10冊を目標に読書をはじめてから気づい...

ニュース一覧

スターを付ける スターを付ける     (107view , 0users)

Full Text Sources

Miscellaneous

Vitamin K antagonists were the only choice for chronic oral anticoagulation for more than half a century. Over the past few years, direct oral anticoagulants have emerged, including one direct thrombin inhibitor (dabigatran etexilate) and three factor Xa inhibitors (apixaban, edoxaban and rivaroxaban). In randomised controlled trials comparing direct oral anticoagulants with traditional vitamin K antagonists, the direct oral anticoagulants all showed a favourable benefit-risk balance in their safety and efficacy profile, in prevention of thromboembolic events in patients with atrial fibrillation and in the prevention and treatment of venous thromboembolism and acute coronary syndrome. In 2008, dabigatran was the first direct oral anticoagulant approved by the European Medicine Agency. Subsequently, rivaroxaban, apixaban and edoxaban were also authorised. This article reviews the evidence related to the use of these drugs.
PMID: 29295790 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード